The inhibitory checkpoints, such as programmed cell death ligand-1 (PD-L1) and cytotoxic T lymphocyte associated antigen 4 (CTLA4) have been demonstrated to inhibit anti-tumor immunity, leading to evade the host immune attack (22, 23). The gene discussed is CTLA4; the disease is neoplasm.